Biocardia reports published study showing helix biotherapeutic delivery system used in cardiamp phase iii heart failure trial has fewest adverse events among competitive delivery systems

San carlos, calif., dec. 01, 2020 (globe newswire) -- biocardia®, inc. [nasdaq: bcda] today announced that the company's proprietary helix biotherapeutic delivery system (the helix system) demonstrated the best safety profile among clinical transendocardial catheter injection systems used for cardiac cell therapy delivery in an in-press corrected proof published in the journal, cardiovascular revascularization medicine. the helix system is being used in the pivotal phase iii cardiamp heart failure trial currently enrolling nationwide for infusion of biocardia's cardiamp cell therapy to the myocardium.
BCDA Ratings Summary
BCDA Quant Ranking